Transforming Hemophilia A Treatment with Bispecific Antibodies – NEJM Group
NEJM Group shared a post on LinkedIn about a recent article by Flora Peyvandi, published in The New England Journal of Medicine, adding;
“Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa, who developed a prophylactic therapy for hemophilia A, have received the 2026 Lasker-DeBakey Clinical Medical Research Award.
For decades, the treatment of hemophilia A rested on a single principle: replacing factor VIII, the missing clotting factor.
Plasma-derived and recombinant factor VIII concentrates transformed a once-fatal disease into a manageable chronic condition through prophylaxis and treatment.
But factor VIII has a relatively short half-life and thus is administered through frequent intravenous infusions, and neutralizing anti-factor VIII antibodies (inhibitors) that render replacement therapy ineffective develop in up to one third of patients with severe hemophilia A.
By showing that the coagulation cascade could be activated in the absence of factor VIII, Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa (of Chugai Pharmaceutical) overcame these limitations.
They developed a bispecific antibody that mimics blood coagulation factor VIlI, an achievement recognized by the 2026 Lasker-DeBakey Clinical Medical Research Award.”
Title: Reengineering Coagulation with a Bispecific Antibody
Authors: Flora Peyvandi
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver